Treatment of malaria with farnesyl protein transferase inhibitors

Abstract

Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent and/or agent for reversing antimalarial resistance. Also disclosed are novel Farnesyl Protein Transferase inhibitors.

What is claimed is:  
     
         1 . A method for treating Malaria comprising administering to a human in need of such treatment an effective amount of a compound selected from:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         2 . The method of  claim 1  wherein the FPT inhibitor is:  
       
         
           
           
               
               
           
         
       
     
     
         3 . A method for treating malaria comprising administering to a patient in need of such treatment an effective amount of a compound used in the method of  claim 1 , in combination with an effective amount of an additional antimalaria agent and/or an additional agent for reversing antimalarial resistance.  
     
     
         4 . A method for treating malaria comprising administering to a patient in need of such treatment an effective amount of the compound used in the method of  claim 2 , in combination with an effective amount of an additional antimalaria agent and/or an additional agent for reversing antimalarial resistance.  
     
     
         5 . The method of  claim 3 , wherein said compound is administered prior to, concurrent to or subsequent to the administration of said additional antimalaria agent and/or said agent for reversing antimalarial resistance.  
     
     
         6 . The method of  claim 3  wherein said additional antimalaria agent is selected from the group comprising: 
 a) quinolines,  
 b) folic acid antagonists,  
 c) sulfonamides, and  
 d) antibiotics.  
 
     
     
         7 . The method of  claim 3  wherein said agent for reversing antimalarial resistance is an inhibitor of multidrug resistance.  
     
     
         8 . The method of  claim 4 , wherein said compound is administered prior to, concurrent to or subsequent to the administration of said additional antimalaria agent and/or said agent for reversing antimalarial resistance.  
     
     
         9 . The method of  claim 4  wherein said additional antimalaria agent is selected from the group comprising: 
 a) quinolines,  
 b) folic acid antagonists,  
 c) sulfonamides, and  
 d) antibiotics.  
 
     
     
         10 . The method of  claim 4  wherein said agent for reversing antimalarial resistance is an inhibitor of multidrug resistance.  
     
     
         11 . A compound selected from:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         12 . A pharmaceutical composition comprising an effective amount of a compound used in the method of  claim 1 , and a pharmaceutically acceptable carrier.  
     
     
         13 . A pharmaceutical composition comprising an effective amount of the compound used in the method of  claim 2 , and a pharmaceutical acceptable carrier.  
     
     
         14 . A pharmaceutical composition comprising an effective amount of a compound of  claim 7  and a pharmaceutically acceptable carrier.  
     
     
         15 . A pharmaceutical composition comprising an effective amount of 
 (1) a compound used in the method of  claim 1;     (2) an additional antimalaria agent; and/or    (3) an agent for reversing antimalarial resistance.    
     
     
         16 . The composition of  claim 11  wherein said additional antimalaria agent is selected from the group comprising: 
 a) quinolines,  
 b) folic acid antagonists,  
 c) sulfonamides, and  
 d) antibiotics.  
 
     
     
         17 . The composition of  claim 11  wherein said agent for reversing antimalarial resistance is an inhibitor of multidrug resistance.  
     
     
         18 . A pharmaceutical composition comprising an effective amount of 
 (1) the compound used in the method of  claim 2;     (2) an additional antimalaria agent; and/or    (3) an agent for reversing antimalarial resistance.    
     
     
         19 . The composition of  claim 14  wherein said additional antimalaria agent is selected from the group comprising: 
 a) quinolines,  
 b) folic acid antagonists,  
 c) sulfonamides, and  
 d) antibiotics.  
 
     
     
         20 . The composition of  claim 14  wherein said agent for reversing antimalarial resistance is an inhibitor of multidrug resistance.